Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer
Compared with palbociclib-fulvestrant, the inavolisib triple regimen is not cost-effective at its current price. A substantial price reduction or careful selection of the target patient may be required for the regimen to be economically viable.
Authors
- Jiaming Zhu
- Zhengxiong Li
- Wen Yao Liu
- Ye Ding
Institutions
- Zhejiang Chinese Medical University (CN)
- China Pharmaceutical University (CN)
- Xuzhou Medical College (CN)
Publication Details
- Journal
- The Breast
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1016/j.breast.2026.104693
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00